< Back to previous page
Researcher
Gilles Defraene
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Radiotherapy (Division)
Member
From1 Oct 2010 → Today
Projects
1 - 4 of 4
- Outcome modeling in Proton TherapyFrom5 Apr 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Towards toxicity reduction in esophageal cancerFrom1 Oct 2021 → 1 Oct 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
- Accurate patient-individual prediction of proton therapy benefit in thoracic cancers using 3D dose maps and radiomicsFrom1 Oct 2020 → 30 Sep 2023Funding: FWO junior postdoctoral fellowship
- Image-based quantification of radiation-induced lung damageFrom1 Oct 2013 → 19 Jan 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 52
- Integrating photon with proton dose-response data alters a pulmonary complication model-based patient selection in esophageal cancer.(2025)Published in: Radiotherapy and OncologyISSN: 0167-8140Volume: 214Pages: 111289
- Dose to the left ventricle is associated to the risk of acute cardiac toxicity in patients with esophageal cancer undergoing trimodality treatment(2025)Published in: Radiotherapy and OncologyISSN: 0167-8140Volume: 209
- Radiotherapy quality assurance in the PROTECT trial - a European randomised phase III-trial comparing proton and photon therapy in the treatment of patients with oesophageal cancer(2025)Published in: Acta OncologicaISSN: 0284-186XVolume: 64Pages: 406 - 414
- Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study(2025)Published in: LUNG CANCERISSN: 0169-5002Volume: 199
- Balancing robustness and adaptation rate for proton therapy of lung cancer patients(2024)Published in: Radiotherapy and OncologyISSN: 0167-8140Volume: 196
- External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts(2024)Published in: Radiotherapy and OncologyISSN: 0167-8140Volume: 193
- Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer(2024)Published in: Radiotherapy and OncologyISSN: 0167-8140Volume: 190
- Clinical implications of dose to functional lung volumes in the trimodality treatment of esophageal cancer(2023)Published in: Acta OncologicaISSN: 0284-186XIssue: 11Volume: 62Pages: 1488 - 1495
- The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study(2022)Published in: Radiotherapy and OncologyISSN: 0167-8140Volume: 176Pages: 127 - 137
- Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancer(2022)Published in: Radiotherapy and OncologyISSN: 0167-8140Volume: 176Pages: 101 - 107